Tang Lingxue, Wang Tong, Zhang Qianqian, Yu Sheng, Li Wen, Yao Senbang, Cheng Huaidong
Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Department of General Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
J Oncol. 2022 Nov 21;2022:2476469. doi: 10.1155/2022/2476469. eCollection 2022.
Ramucirumab, as a vascular endothelial growth factor receptor-2 inhibitor, was first approved in 2014 for treated advanced or metastatic gastric/gastroesophageal junction (GEJ) adenocarcinoma. This study deeply analyzed the efficacy and safety of advanced or metastatic cancer treated with ramucirumab, which included 11 global, double-blind, phase 3 randomized controlled trials with a total of 7410 patients. Subgroup analysis based on different cancer types showed that standard regimens plus ramucirumab significantly increased progression-free survival and overall survival compared with placebo groups in patients with advanced non-small-cell lung cancer (NSCLC), hepatocellular carcinoma, gastric cancer, or GEJ adenocarcinoma. Although a higher proportion of patients achieved overall response and disease control than those treated with placebo, the overall response was not statistically significant between the two groups in advanced NSCLC. Grade 3 or worse treatment-emergent adverse events (TEAEs) that occurred in at least 5% of patients were neutropenia (30.5% in the ramucirumab group vs. 23.5% in the placebo group), leucopenia (14.8% vs. 9.2%), weight decreased (14.2% vs. 8.0%), myalgia (11.7% vs. 7.7%), fatigue (10.9% vs. 7.7%), hypertension (9.2% vs. 2.3%), and anaemia (6.2% vs. 7.7%). In the TEAEs of special interest, the ramucirumab group had a significantly higher incidence of bleeding (mainly grade 1-2 epistaxis and gastrointestinal bleeding), hypertension, proteinuria, liver injury/failure (grade 1-2), venous thromboembolism (grade 1-2), and gastrointestinal perforation (grade ≧3) than the control group.
雷莫西尤单抗作为一种血管内皮生长因子受体-2抑制剂,于2014年首次获批用于治疗晚期或转移性胃/胃食管交界(GEJ)腺癌。本研究深入分析了雷莫西尤单抗治疗晚期或转移性癌症的疗效和安全性,该研究包括11项全球双盲3期随机对照试验,共纳入7410例患者。基于不同癌症类型的亚组分析表明,在晚期非小细胞肺癌(NSCLC)、肝细胞癌、胃癌或GEJ腺癌患者中,与安慰剂组相比,标准方案加雷莫西尤单抗显著提高了无进展生存期和总生存期。虽然达到总体缓解和疾病控制的患者比例高于安慰剂治疗组,但在晚期NSCLC患者中,两组之间的总体缓解率无统计学差异。至少5%的患者发生的3级或更严重的治疗中出现的不良事件(TEAE)有中性粒细胞减少(雷莫西尤单抗组为30.5%,安慰剂组为23.5%)、白细胞减少(14.8%对9.2%)、体重下降(14.2%对8.0%)、肌痛(11.7%对7.7%)、疲劳(10.9%对7.7%)、高血压(9.2%对2.3%)和贫血(6.2%对7.7%)。在特别关注的TEAE中,雷莫西尤单抗组出血(主要为1-2级鼻出血和胃肠道出血)、高血压、蛋白尿、肝损伤/衰竭(1-2级)、静脉血栓栓塞(1-2级)和胃肠道穿孔(≥3级)的发生率显著高于对照组。